ArticlePloS one2019
Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Implementing HIV teams sustainably improves HIV indicator condition testing rates in hospitals in the Netherlands: the #aware.hiv clinical trial.AIDS (London, England) · 2025Trial
- Article
- Missed Opportunities for HIV Testing in Hospitalised Adults in Türkiye: Indicator Conditions and Testing Coverage in a National Multicentre Point-Prevalence Survey (HIV-ICs-TR).Scientific reports · 2026Article
- The Forgotten Test: Missed Opportunities for HIV Diagnosis and Survival Outcomes in Advanced HIV Disease.Viruses · 2026Article
- Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.HIV medicine · 2025Article
- Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999-2023).Infection · 2025Observational
- [Implementation of an early HIV diagnosis and treatment program in a hospital emergency department].Anales del sistema sanitario de Navarra · 2025Article
- High acceptability of point-of-care HIV testing at the colposcopy outpatient clinic in hospitals in the Netherlands.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Missed opportunities for early HIV diagnosis in Greece: The MORFEAS study, 2019 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Knowledge and Awareness of Risk Factors for HIV Infection and about HIV Testing among Medical Students in Warsaw.Viruses · 2024Article
- Missed Opportunities for HIV Diagnosis and Their Clinical Repercussions in the Portuguese Population-A Cohort Study.Pathogens (Basel, Switzerland) · 2024Article
- Prevalence of HIV in people with potential HIV-indicator conditions in Germany: an analysis of data from statutory health insurances.EClinicalMedicine · 2024Article
- Enhancing indicator condition-guided HIV testing in Taiwan: a nationwide case-control study from 2009 to 2015.BMC public health · 2024Article
- Systematic Review: Strategies for Improving HIV Testing and Detection Rates in European Hospitals.Microorganisms · 2024Review
- Prevalence, characteristics and challenges of late HIV diagnosis in Germany: an expert narrative review.Infection · 2023Review
- Optimization of HIV testing services in Germany using HIV indicator diseases: study protocol of the HeLP study.Archives of public health = Archives belges de sante publique · 2023Article
- HIV-Indicator Condition Guided Testing in a Hospital Setting.Life (Basel, Switzerland) · 2023Article
- [Emergency detection of HIV infection in patients consulting for conditions potentially related to occult infection: Initial results of the "Urgències VIHgila" program].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Impact of the COVID 19 pandemic on new diagnoses of HIV infection.Medicina clinica (English ed.) · 2023Article
- Mapping hematologists' HIV testing behavior among lymphoma patients-A mixed-methods study.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries.
methodsIndividuals aged 18-65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015.
resultsOf 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5-3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis.
conclusionThe study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.